Paragon Vision Sciences, Inc.

Paragon Vision Sciences develops innovative vision correction solutions, focusing on corneal refractive therapy through FDA-approved contact lenses that reshape the cornea to alleviate myopia. Paragon Vision Sciences is dedicated to innovative vision correction solutions, and was acquired by Summit Partners in 1995. The company is headquartered in Mesa, US. There is no information available regarding subsidiaries or previous pivots in business strategy.

The founder's history is not provided. Paragon Vision Sciences specializes in innovative vision correction solutions, primarily through its flagship product, the Paragon CRT® (Corneal Refractive Therapy) lenses. These FDA-approved, non-surgical contact lenses are designed to be worn overnight, gently reshaping the cornea to correct nearsightedness (myopia) while the user sleeps. This allows individuals to experience improved vision without the need for daytime glasses or contact lenses.

The treatment duration typically spans 7 to 14 days to achieve optimal unaided vision throughout the day. Paragon CRT® lenses cater to a diverse clientele, including patients struggling with myopia in over 50 countries, particularly prominent markets such as the United States, Canada, Australia, and several European nations. By addressing the challenges associated with myopia, including eyestrain and potential long-term complications, these lenses offer a practical solution for active individuals and those looking for an alternative to traditional vision correction methods. Paragon Vision Sciences generates revenue primarily through the direct sales of its Paragon CRT® contact lenses to eye care practitioners, who then dispense them to individual patients.

The company operates on a B2B model, establishing partnerships with optometrists and eye care clinics that serve as key distributors of their products. Revenue is derived from these transactions, where practitioners order CRT lenses in bulk to cater to the needs of their patients. The pricing structure reflects the value of the lenses as a non-surgical treatment option for myopia, with the cost being determined by healthcare providers based on their practice models. This approach allows for flexibility and adaptability in pricing, ensuring that practitioners can offer Paragon CRT® as a competitive option within their vision correction services.

Paragon Vision Sciences plans to leverage its previous acquisition by Summit Partners in 1995 to expand its product offerings and geographic reach. Although specific new products are not mentioned, the company aims to enhance its presence in existing markets while exploring opportunities in new regions. The company's future growth strategy appears focused on solidifying partnerships with eye care clinics and improving distribution channels to better serve patients' needs.